Literature DB >> 17456035

RNAi silencing in mouse models of neurodegenerative diseases.

Mohamed H Farah1.   

Abstract

RNA interference (RNAi) has emerged as a potential therapeutic approach for neurodegenerative diseases, particularly those associated with autosomal dominant patterns of inheritance. In proof of concept experiments, several groups have demonstrated efficacy of using viral vectors expressing short hairpin RNA (shRNA) directed against therapeutically relevant genes in mouse models of neurodegenerative diseases, including spinocerebellar ataxia, Amyotrophic Lateral Sclerosis, Huntington's Disease and amyloidosis (a pathological aspect of Alzheimer's Disease). Although viral-based RNAi has limitations that most likely will preclude its usage in humans, a few recent developments underscore the potential of non-viral-based delivery of relevant RNAi as therapeutics for neurodegenerative diseases. Here, I will review the recent literature on effectiveness of RNAi as a therapeutic strategy in mouse models of neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17456035     DOI: 10.2174/156720107780362276

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  11 in total

1.  Mu opioid receptor knockdown in the substantia nigra/ventral tegmental area by synthetic small interfering RNA blocks the rewarding and locomotor effects of heroin.

Authors:  Y Zhang; M Landthaler; S D Schlussman; V Yuferov; A Ho; T Tuschl; M J Kreek
Journal:  Neuroscience       Date:  2008-10-02       Impact factor: 3.590

2.  Chitosan-Mangafodipir nanoparticles designed for intranasal delivery of siRNA and DNA to brain.

Authors:  Juan Sanchez-Ramos; Shijie Song; Xiaoyuan Kong; Parastou Foroutan; Gary Martinez; William Dominguez-Viqueria; Shyam Mohapatra; Subhra Mohapatra; Reka A Haraszti; Anastasia Khvorova; Neil Aronin; Vasyl Sava
Journal:  J Drug Deliv Sci Technol       Date:  2017-11-21       Impact factor: 3.981

Review 3.  Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?

Authors:  Lisa Gherardini; Giuseppe Bardi; Mariangela Gennaro; Tommaso Pizzorusso
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

4.  Lipid nanoparticle delivery systems for siRNA-based therapeutics.

Authors:  C Wan; T M Allen; P R Cullis
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

5.  Therapeutic interventions in the primary hereditary ataxias.

Authors:  Gonzalo J Revuelta; George R Wilmot
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

6.  Inactivation of Drosophila Huntingtin affects long-term adult functioning and the pathogenesis of a Huntington's disease model.

Authors:  Sheng Zhang; Mel B Feany; Sudipta Saraswati; J Troy Littleton; Norbert Perrimon
Journal:  Dis Model Mech       Date:  2009-04-06       Impact factor: 5.758

Review 7.  Lentiviral delivery of short hairpin RNAs.

Authors:  N Manjunath; Haoquan Wu; Sandesh Subramanya; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2009-03-31       Impact factor: 15.470

Review 8.  The promises and pitfalls of RNA-interference-based therapeutics.

Authors:  Daniela Castanotto; John J Rossi
Journal:  Nature       Date:  2009-01-22       Impact factor: 49.962

9.  Effective inhibition of different Japanese encephalitis virus genotypes by RNA interference targeting two conserved viral gene sequences in vitro and in vivo.

Authors:  Lei Yuan; Xiaojuan Feng; Xuelian Gao; Yu Luo; Chaoyue Liu; Peng Liu; Guolin Yang; Hong Ren; Rong Huang; Yalan Feng; Jian Yang
Journal:  Virus Genes       Date:  2018-09-18       Impact factor: 2.332

10.  Profiling essential genes in human mammary cells by multiplex RNAi screening.

Authors:  Jose M Silva; Krista Marran; Joel S Parker; Javier Silva; Michael Golding; Michael R Schlabach; Stephen J Elledge; Gregory J Hannon; Kenneth Chang
Journal:  Science       Date:  2008-02-01       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.